Breeze Holdings Acquisition Corp. shareholders have approved the business combination with YD Biopharma Limited.
The combined company will be named YD Bio Limited and is expected to trade on Nasdaq under the ticker symbol "YDES".
The closing of the transaction is expected to occur within the next two weeks.
Business Combination Approval
Stockholders voted in favor of the Business Combination with a significant majority.
New Ticker Symbol
The combined company will trade under the ticker symbol "YDES" on Nasdaq.
Closing Timeline
The transaction is expected to close within two weeks pending customary conditions.
- The approval of the business combination solidifies the path for YD Biopharma Limited to merge with Breeze Holdings Acquisition Corp.
- Trading under the new ticker symbol "YDES" on Nasdaq signifies a new chapter for the combined company.
- Investors are anticipating the closing of the transaction in the coming weeks, which could impact the stock performance.
The approval of the business combination marks a significant milestone for both Breeze Holdings Acquisition Corp. and YD Biopharma Limited, setting the stage for a new merged entity on the Nasdaq.